Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Zimmermann

Showing results (251-260 of 279) with videos related to

Pageof 28
Sort By:
Blood|September 24, 2017
Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALLFranco Locatelli, Maria Grazia Valsecchi, Anja Möricke, et al.
Haematologica|July 28, 2011
Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemiaBrian V Balgobind, Iris H I M Hollink, Susan T C J M Arentsen-Peters, et al.
Leukemia|December 7, 2019
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trialAndishe Attarbaschi, Georg Mann, Martin Zimmermann, et al.
Leukemia|May 18, 2022
Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolutionPaulina Richter-Pechańska, Joachim B Kunz, Tobias Rausch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2023
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized StudyValentino Conter, Maria Grazia Valsecchi, Gunnar Cario, et al.
Blood|July 29, 2015
Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international studyHiroto Inaba, Yinmei Zhou, Oussama Abla, et al.
Leukemia|November 27, 2019
Correction: Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trialMartin G Sauer, Peter J Lang, Michael H Albert, et al.
Bone Marrow Transplantation|May 16, 2019
Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALLFlorian Babor, Christina Peters, Angela R Manser, et al.
Blood|August 27, 2013
Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study groupEva A Coenen, C Michel Zwaan, Dirk Reinhardt, et al.
Leukemia|October 4, 2019
Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trialMartin G Sauer, Peter J Lang, Michael H Albert, et al.
Pageof 28

Showing results (251-260 of 279) with videos related to

Sort By:
Pageof 28
Blood|September 24, 2017
Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALLFranco Locatelli, Maria Grazia Valsecchi, Anja Möricke, et al.
Haematologica|July 28, 2011
Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemiaBrian V Balgobind, Iris H I M Hollink, Susan T C J M Arentsen-Peters, et al.
Leukemia|December 7, 2019
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trialAndishe Attarbaschi, Georg Mann, Martin Zimmermann, et al.
Leukemia|May 18, 2022
Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolutionPaulina Richter-Pechańska, Joachim B Kunz, Tobias Rausch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2023
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized StudyValentino Conter, Maria Grazia Valsecchi, Gunnar Cario, et al.
Blood|July 29, 2015
Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international studyHiroto Inaba, Yinmei Zhou, Oussama Abla, et al.
Leukemia|November 27, 2019
Correction: Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trialMartin G Sauer, Peter J Lang, Michael H Albert, et al.
Bone Marrow Transplantation|May 16, 2019
Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALLFlorian Babor, Christina Peters, Angela R Manser, et al.
Blood|August 27, 2013
Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study groupEva A Coenen, C Michel Zwaan, Dirk Reinhardt, et al.
Leukemia|October 4, 2019
Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trialMartin G Sauer, Peter J Lang, Michael H Albert, et al.
Pageof 28